Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR

Animals Antibodies, Monoclonal, Humanized / pharmacology Apoptosis Cell Proliferation ErbB Receptors / genetics Glioblastoma / drug therapy Humans Immunoconjugates / pharmacology Mice Mice, Nude Mutation Phosphorylation Tumor Cells, Cultured Xenograft Model Antitumor Assays

Journal

Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535

Informations de publication

Date de publication:
06 2020
Historique:
received: 16 06 2019
revised: 25 02 2020
accepted: 30 03 2020
pubmed: 7 5 2020
medline: 29 4 2021
entrez: 7 5 2020
Statut: ppublish

Résumé

Glioblastomas commonly (40%) exhibit epidermal growth factor receptor (

Identifiants

DOI: 10.1158/1535-7163.MCT-19-0609 PMID: 32371586
pubmed: 32371586
pii: 1535-7163.MCT-19-0609
doi: 10.1158/1535-7163.MCT-19-0609
doi:

Substances chimiques

ABT-414 0
Antibodies, Monoclonal, Humanized 0
Immunoconjugates 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1328-1339

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Caroline von Achenbach (C)

Laboratory of Molecular Neuro-Oncology, Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.

Manuela Silginer (M)

Laboratory of Molecular Neuro-Oncology, Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.

Vincent Blot (V)

Abbvie Inc., North Chicago, Illinois.

William A Weiss (WA)

Departments of Neurology, Pediatrics, Neurosurgery, Brain Tumor Research Center, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
ORCID: 0000-0003-2230-9132

Michael Weller (M)

Laboratory of Molecular Neuro-Oncology, Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland. michael.weller@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Glioblastome › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Immunoconjugués › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Souches mutantes de souris › Souris nude › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Métabolisme › Phosphorylation › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Depatuxizumab Mafodotin (ABT-414)-induced...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Depatuxizumab Mafodotin (ABT-414)-induced...